# Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

> **NCT01269047** · PHASE4 · COMPLETED · sponsor: **Albert Einstein College of Medicine** · enrollment: 37 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Pramlintide
- **DRUG:** Exenatide
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT01269047
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2016-08
- **Final completion:** 2016-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01269047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01269047, "Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01269047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*